Eupraxia Pharmaceuticals (EPRX) Projected to Post Quarterly Earnings on Wednesday

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Stock Performance

Eupraxia Pharmaceuticals stock traded up $0.13 during midday trading on Monday, hitting $3.93. 422 shares of the company's stock were exchanged, compared to its average volume of 14,573. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $4.48. The firm has a 50-day moving average of $3.62 and a two-hundred day moving average of $3.35. The company has a market cap of $140.89 million and a PE ratio of -5.46.

Analyst Ratings Changes

Separately, Craig Hallum started coverage on Eupraxia Pharmaceuticals in a research report on Friday, February 21st. They issued a "buy" rating and a $12.00 price objective for the company.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.